



Recent Technological Advancements in the Treatment of Otitis Media (OM)

Sankar K^{1*} and Mohammed Khan MY²

¹Assistant Professor, Department of Biomedical Engineering, Rajalakshmi Engineering College, India

²Student, Department of Biomedical Engineering, Rajalakshmi Engineering College, India

***Corresponding author:** Krishnakumar Sankar, Department of Biomedical Engineering, Rajalakshmi Engineering College, Vellore - Chennai Rd, Rajalakshmi Nagar, Thandalam, Mevalurkuppam, Chennai, Tamil Nadu- 602105, India, Tel: +91 90035 82892; Email: mohamedyusuf280904@gmail.com

Received Date: November 28, 2024; **Published Date:** December 02, 2024

Keywords

Ear Infections; Otitis Media; Otitis Externa; Smartphone-Based Otoscopy; Nanotechnology; Drug Delivery Systems; Bioengineered Tympanic Membranes; Artificial Intelligence (AI); Machine Learning; Robotic-Assisted Surgery

Abbreviations

AMSA: Automatic Manosonic Aerosol Generator; AOM: Acute Otitis Media; EOM: Eosinophilic Otitis Media; OM: Otitis Media; OME: Otitis Media with Effusion; QoL: Quality of Life; RCT: Randomized Clinical Trials; TMJ: Temporomandibular Joint.

Introduction

One of the most common prevailing ailments throughout the world especially in children is Otitis media (OM) which encompasses otitis media with effusion (OME) and acute otitis media (AOM). Some of the treatment methodologies that OM has impacted are antibiotics, surgical techniques, and pneumococcal conjugate vaccinations. This review investigates the recent advancements in epidemiology, diagnostics, and therapeutic techniques with the help of state-of-the-art therapies and international guidelines.

The Effects of Epidemiological Changes on Acute Otitis Media (AOM)

The epidemiology of AOM underwent significant changes since the use of pneumococcal conjugate vaccinations.

The increase in Haemophilus influenzae and non-vaccine Streptococcus pneumonia serotypes has challenged the existing diagnostic and therapeutic methods. This led to the declination of vaccine-targeted serotypes [1,2]. The prevalence of non-vaccine Streptococcus pneumoniae serotypes, including Haemophilus influenzae, has increased, upending established diagnostic and therapeutic paradigms, while vaccine-targeted Streptococcus pneumoniae serotypes have declined [3].

Despite technological and medical advancements, there exist certain difficulties. Some of the major obstacles include misdiagnosis, abuse of antibiotics, and antimicrobial resistance. Updated Italian guidelines emphasize high-dose amoxicillin for severe AOM and advocate therapies based on age and severity. This includes watchful waiting for mild instances in older children [4]. European recommendations emphasize the importance of standardized, high-quality guidelines to fight resistance developments [5]. A high association between antibiotic stewardship and immunization is reflected in these changes.

Developments in Comparative Efficacy and Antibiotic Stewardship

Despite newer studies posing doubts about their wide usage, antibiotic prevails to be the key component of AOM therapy. Although they shorten the duration of symptoms in extreme cases, antibiotics provide minimal advantages above placebo for primary outcomes including pain alleviation, according to a systematic assessment of randomized clinical trials

(RCTs) conducted between 2000 and 2019 [6]. Amoxicillin, amoxicillin-clavulanate, cefdinir, and azithromycin are typical antibiotics used in over a million children with uncomplicated AOM, according to a retrospective cohort investigation. As the first-line treatment, amoxicillin was further supported by the fact that it had the lowest combined failure and recurrence rates. Broad-spectrum antibiotics were more likely to cause adverse events, like gastrointestinal problems, which highlights the need for specialized treatments [7].

This trend is also reflected in Japanese guidelines, which classify treatment according to the severity of the ailment. While a watchful waiting strategy is recommended for mild instances in older children, prompt antibiotic therapy is advised for severe cases and younger children [2]. This is in line with international initiatives to reduce the overuse of antibiotics and fight resistance.

Recurrent AOM: Surgical and Non-Surgical Treatments

A unique clinical problem, recurrent AOM frequently necessitates a mix of medicinal and surgical therapy. Although tympanostomy tube implantation is still a common practice, new research casts doubt on its effectiveness in comparison to episodic antibiotic therapy. There were no appreciable variations in recurrence rates between the two methods in a two-year randomized study. Though there were no significant reductions in overall recurrence rates, tympanostomy proved to be advantageous in lessening the pain episodes thereby improving the QoL [8].

The technological advancements ensure efficient treatment methodologies and outcomes for eosinophilic otitis media (EOM), a type of OM related to bronchial asthma. Conventional treatment methodology to treat EOM is the administration of corticosteroids which is a middle ear infection caused by Type 2 inflammations. The advent of the revolutionary stage is here with the development of medications that provide disease-specific treatments [9].

Acute Mastoiditis and Other AOM Complications

One of the fatal side effects of AOM is acute mastoiditis which primarily affects Young Children. Some of the significant risk factors are increased inflammatory markers, high fever, and delayed treatment. Intravenous cephalosporins are one of the promising technologies used with other antibiotics to treat this illness [10]. To avoid the possibility of cerebral abscesses or sigmoid sinus thrombosis, there may be a necessity for surgical procedures like mastoidectomy [10]. Early diagnosis and management are mandatory to lessen the morbidity and mortality of the disease. A thorough understanding of these dangers will be useful to understand the importance of prompt treatment after AOM is identified.

Advances in the Management of Otitis Media with Effusion (OME)

OME put forth challenges at various levels in terms of diagnosis and management. Risk levels are used to categorize OME cases accompanied by Down syndrome or cleft palate based on updated Japanese recommendations. The treatment recommendations are based on the clinical severity of the disease and otoscopic results [11]. A pilot study where adults were treated for OME using an automatic manometric aerosol generator (AMSA) showed promising outcomes. Notably, 80% of them experienced partial or total remission and improvements in the parameters associated with tympanometry. The significance of inhaled mucolytics and steroids was highlighted in the study despite more investigations being required for confirming the outcomes [12].

Tympanostomy and myringotomy prove to be appropriate choices for persistent effusion. An experimental trial that involved 318 kids with OME demonstrated successful results. Low recurrence rates and favorable safety profiles prove the importance of customized treatment plans for each patient. It is important to note that all those children who were involved in the trial were admitted to the hospital for various therapies including surgery and medication [13,14].

Chronic Otitis Media's Effect on Hearing and Development

Hearing and cognitive development can be significantly impacted by chronic otitis media, especially in young individuals. Tympanometry findings and hearing thresholds were significantly impaired in 201 children with OME in a Polish study. Despite inherited factors impacting the course Even though inherited factors frequently impacted the course of the disease, auditory outcomes improved due to efficient ventilation drainage [11].

Failing to comply with the early management procedures of OME-related hearing loss, will put the speech and language milestones at risk. Two of the best strategies for OME-related issues are age-appropriate therapies and audiological evaluations [12].

New Perspectives and Etiological Insights

The studies conducted in the past 5 years provide insights into the less well-known etiological variables of OM. Mandibular malposition and dysfunction of the temporomandibular joint (TMJ) are related to recurrent and chronic OMs. Middle ear disorders can result from stomatognathic system dysfunction, which also affects Eustachian tube function. Orthognathic therapies that address these dysfunctions have the potential to stop recurrent episodes of otitis media [15].

The connection between Type 2 inflammation and bronchial asthma and eosinophilic otitis media emphasizes how crucial it is to comprehend inflammatory mechanisms. Biologics are a major advancement since they provide tailored therapy for illnesses that were previously treated with corticosteroids alone [9].

Global Standards and the Stewardship of Antibiotics

Addressing regional differences in otitis media care requires harmonizing recommendations. Significant variation in recommendations was found in a survey of European guidelines, many of which had poor methodological quality [5]. The recommended first-line treatment is still high-dose amoxicillin, but differences in antibiotic stewardship underscore the need for evidence-based revisions [4,5]. The 2018 Japanese recommendations offer a strong framework that takes into account developments in vaccines and bacteriological alterations. Stratified therapy recommendations highlight the importance of patient-tailored therapies and accurate otoscopic findings. Following this methodology will ensure alignment with international initiatives in advancing AOM and OME interventions [2].

Research Gaps and Future Directions

Encouraging opportunities that ensure better management of OM are always available to the researchers to explore. The development of pneumococcal vaccinations targeting non-vaccine serotypes ensures reducing the burden of OM [3]. Some of the path-breaking discoveries that call for extensive clinical trials for OME are biological therapy and Aerosol-based treatments [12]. Two of the foremost concerns in OM management are filling in the gaps in international recommendations and promising antibiotic stewardship [5]. Well-coordinated, higher recommendations have the chance to reduce the resistance trends thereby achieving the best possible treatment outcomes. The developmental effects of chronic OM, especially in pediatric groups, will be further researched resulting in customized disease management options [14].

Conclusion

Otitis media is still a complex clinical problem that calls for a multidimensional strategy that incorporates epidemiological knowledge, accurate diagnosis, and cutting-edge therapies. The difficulty in managing OME and AOM is emphasized by the antibiotic stewardship, interaction of immunization, and customized therapies. While harmonized recommendations help address regional inequalities in care, advancements in surgical innovations, aerosol-based treatments, and biologic therapeutics provide promise for improved results. A thorough, evidence-based approach will be necessary as

research advances to address the changing requirements of patients of all ages.

Acknowledgment

The authors thank the Department of Biomedical Engineering, Rajalakshmi Engineering College in providing insights into the successful completion of the article.

References

1. Martin DL, Perez RP, Campos LM, Alvarez JA, de la Calle Cabrera T, et al. (2023) Update of the consensus document on the aetiology, diagnosis and treatment of acute otitis media and sinusitis. *An Pediatr* 98(5): 362-372.
2. Hayashi T, Kitamura K, Hashimoto S, Hotomi M, Kojima H, et al. (2020) Clinical practice guidelines for the diagnosis and management of acute otitis media in children- 2018 update. *Auris Nasus Larynx* 47(4): 493-526.
3. El Feghaly RE, Nedved A, Katz SE, Frost HM (2023) New insights into the treatment of acute otitis media. *Expert Rev Anti Infect Ther* 21(5): 523-534.
4. Marchisio P, Galli L, Bortone B, Ciarcia M, Motisi MA, et al. (2019) Updated guidelines for the management of acute otitis media in children by the Italian society of pediatrics: treatment. *Pediatr Infect Dis J* 38(12S): S10-S21.
5. Suzuki HG, Dewez JE, Nijman RG, Yeung S (2020) Clinical practice guidelines for acute otitis media in children: a systematic review and appraisal of European national guidelines. *BMJ Open* 10(5): e035343.
6. Holm NH, Rusan M, Ovesen T (2020) Acute otitis media and antibiotics: a systematic review. *Dan Med J* 67(11): A04200272.
7. Frost HM, Bizune D, Gerber JS, Hersh AL, Hicks LA, et al. (2022) Amoxicillin versus other antibiotic agents for the treatment of acute otitis media in children. *J Pediatr* 251: 98-104.
8. Hoberman A, Preciado D, Paradise JL, Chi DH, Haralam M, et al. (2021) Tympanostomy tubes or medical management for recurrent acute otitis media. *N Engl J Med* 384(19): 1789-1799.
9. Iino Y (2023) Eosinophilic otitis media: state-of-the-art diagnosis and treatment. *Auris Nasus Larynx* 50(4): 479-489.
10. Cassano P, Ciprandi G, Passali D (2020) Acute mastoiditis

in children. *Acta Biomed* 91(Suppl 1): 54-59.

11. Hidaka H, Ito M, Ikeda R, Kamide Y, Kuroki H, et al. (2023) Clinical practice guidelines for the diagnosis and management of otitis media with effusion (OME) in children in Japan- 2022 update. *Auris Nasus Larynx* 50(5): 655-699.
12. Zasadzinska-Stempniak K, Karwat B, Jarmolowicz-Aniolkowska N, Zajackiewicz H (2023) Resolution of otitis media with effusion in adults after a three-day course of treatment with a manosonic nebulizer- a pilot study. *Medicina* 59(2): 201.
13. Partycka-Pietrzyk K, Niedzielski A, Kasprzyk A, Jablonska J, Mielnik-Niedzielska G, et al. (2023) Audiometric outcomes of ventilation drainage treatment for otitis media with effusion in children: Implications for speech development and hearing loss. *Med Sci Monit* 29: e941350.
14. Zhang Y, Fu Y (2022) Different treatment methods and efficacy analysis of otitis media with effusion in children with different hearing loss. *J Clin Otorhinolaryngol Head Neck Surg* 36(10):731-735.
15. Bernkopf E, Cristalli G, de Vincentiis GC, Bernkopf G, Capriotti V (2022) Temporomandibular joint and otitis media: a narrative review of implications in etiopathogenesis and treatment. *Medicina* 58(12): 1806.